Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | TACR3 | P29371 | 12/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1717308 | 1.00 | CYP2C9 (0.53) | CYP2C9TACR3RIPK1PIK3CDPIK3CG | |
| SCHEMBL1717479 | 0.97 | CYP2C9 (0.50) | CYP2C9TACR3RIPK1PIK3CDPIK3CG | |
| SCHEMBL1717422 | 0.92 | RIPK1 (0.46) | CYP2C9TACR3RIPK1PIK3CDPIK3CG | |
| SCHEMBL1717926 | 0.91 | TACR3 (0.45) | CYP2C9TACR3RIPK1PIK3CDPIK3CG | |
| SCHEMBL1942021 | 0.91 | CYP2C9 (0.55) | CYP2C9TACR3RIPK1 | |
| SCHEMBL1717860 | 0.91 | RIPK1 (0.43) | CYP2C9TACR3RIPK1PIK3CDPIK3CG | |
| SCHEMBL1717601 | 0.89 | CYP2C9 (0.58) | CYP2C9TACR3RIPK1PPARG | |
| SCHEMBL1717544 | 0.89 | CYP2C9 (0.53) | CYP2C9TACR3RIPK1PIK3CG | |
| SCHEMBL1716839 | 0.89 | MEN1 (0.43) | CYP2C9TACR3RIPK1PIK3CDPIK3CG | |
| SCHEMBL1717965 | 0.89 | RIPK1 (0.43) | CYP2C9TACR3RIPK1PIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150534-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-01-11 | — | — | EP | claimed |
| US-20110130420-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S | 2011-06-02 | — | — | US | claimed |
| US-8173639-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| EP-2150534-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-01-11 | — | — | EP | disclosed |
| EP-2150534-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-01-11 | — | — | EP | disclosed |
| US-20110130420-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S | 2011-06-02 | — | — | US | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| WO-2008131779-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | CYP2C9 2755/4885TACR3 30/4885RIPK1 3087/4885 |
| US-20110130420-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, KCNJ3 | CYP2C9 3293/4885TACR3 70/4885RIPK1 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.